Human calcitonin in the treatment of renal osteodystrophy

Kenneth Farrington; Zachariah Varghese; John F. Moorhead

Human calcitonin in the treatment of renal osteodystrophy

Kenneth Farrington, Zachariah Varghese, John F. Moorhead

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

The effects of HCT (0.5 to 1 mg/day subcutaneously), used singly and in combination with a small dose of 1,25-(OH)₂D₃ (0.25 μg/day by mouth), have been studied in 16 hemodialysis patients with hypercalcemic hyperparathyroid bone disease for a mean period of 6 months. An initial improvement occurred in plasma hydroxyproline and parathyroid hormone levels, but there were later rebound increases. There was little overall effect on bone histology, and 10 of the patients had side effects from treatment. HCT in this dose, alone or in combination with small doses of 1,25-(OH)₂D₃, does not appear to have a major role in the treatment of the hypercalcemic hyperparathyroidism of renal osteodystrophy.

Original language	English
Pages (from-to)	299-306
Number of pages	8
Journal	Journal of Laboratory and Clinical Medicine
Volume	96
Issue number	2
Publication status	Published - 1980

Keywords

(1 25-(OH)D)
1
25-dihydroxycholecalciferol
chronic renal failure
CRF
HCT
human calcitonin
i-PTH
immunoreactive PTH
maintenance hemodialysis treatment
MHT
parathyroid hormone
PTH

Cite this

@article{312d409bebe74b64a67d71f147cf3570,

title = "Human calcitonin in the treatment of renal osteodystrophy",

abstract = "The effects of HCT (0.5 to 1 mg/day subcutaneously), used singly and in combination with a small dose of 1,25-(OH)2D3 (0.25 μg/day by mouth), have been studied in 16 hemodialysis patients with hypercalcemic hyperparathyroid bone disease for a mean period of 6 months. An initial improvement occurred in plasma hydroxyproline and parathyroid hormone levels, but there were later rebound increases. There was little overall effect on bone histology, and 10 of the patients had side effects from treatment. HCT in this dose, alone or in combination with small doses of 1,25-(OH)2D3, does not appear to have a major role in the treatment of the hypercalcemic hyperparathyroidism of renal osteodystrophy.",

keywords = "(1 25-(OH)D), 1, 25-dihydroxycholecalciferol, chronic renal failure, CRF, HCT, human calcitonin, i-PTH, immunoreactive PTH, maintenance hemodialysis treatment, MHT, parathyroid hormone, PTH",

author = "Kenneth Farrington and Zachariah Varghese and Moorhead, {John F.}",

year = "1980",

language = "English",

volume = "96",

pages = "299--306",

journal = "Journal of Laboratory and Clinical Medicine",

issn = "0022-2143",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Human calcitonin in the treatment of renal osteodystrophy

AU - Farrington, Kenneth

AU - Varghese, Zachariah

AU - Moorhead, John F.

PY - 1980

Y1 - 1980

N2 - The effects of HCT (0.5 to 1 mg/day subcutaneously), used singly and in combination with a small dose of 1,25-(OH)2D3 (0.25 μg/day by mouth), have been studied in 16 hemodialysis patients with hypercalcemic hyperparathyroid bone disease for a mean period of 6 months. An initial improvement occurred in plasma hydroxyproline and parathyroid hormone levels, but there were later rebound increases. There was little overall effect on bone histology, and 10 of the patients had side effects from treatment. HCT in this dose, alone or in combination with small doses of 1,25-(OH)2D3, does not appear to have a major role in the treatment of the hypercalcemic hyperparathyroidism of renal osteodystrophy.

AB - The effects of HCT (0.5 to 1 mg/day subcutaneously), used singly and in combination with a small dose of 1,25-(OH)2D3 (0.25 μg/day by mouth), have been studied in 16 hemodialysis patients with hypercalcemic hyperparathyroid bone disease for a mean period of 6 months. An initial improvement occurred in plasma hydroxyproline and parathyroid hormone levels, but there were later rebound increases. There was little overall effect on bone histology, and 10 of the patients had side effects from treatment. HCT in this dose, alone or in combination with small doses of 1,25-(OH)2D3, does not appear to have a major role in the treatment of the hypercalcemic hyperparathyroidism of renal osteodystrophy.

KW - (1 25-(OH)D)

KW - 1

KW - 25-dihydroxycholecalciferol

KW - chronic renal failure

KW - CRF

KW - HCT

KW - human calcitonin

KW - i-PTH

KW - immunoreactive PTH

KW - maintenance hemodialysis treatment

KW - MHT

KW - parathyroid hormone

KW - PTH

UR - http://www.scopus.com/inward/record.url?scp=0018931186&partnerID=8YFLogxK

M3 - Article

C2 - 7400664

AN - SCOPUS:0018931186

SN - 0022-2143

VL - 96

SP - 299

EP - 306

JO - Journal of Laboratory and Clinical Medicine

JF - Journal of Laboratory and Clinical Medicine

IS - 2

ER -

Human calcitonin in the treatment of renal osteodystrophy

Abstract

Keywords

Other files and links

Fingerprint

Cite this